Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma: A phase II, pharmacokinetic (PK) and biological correlative study with FDG-PET imaging.

@article{Beeram2004DurableDS,
  title={Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma: A phase II, pharmacokinetic (PK) and biological correlative study with FDG-PET imaging.},
  author={Muralidhar Beeram and Eric K. Rowinsky and Geoffrey Roger Weiss and Samira Syed and Alain C. Mita and Amita Patnaik and Monica M. Mita and Michelle Goldston and Johann S de Bono and Anthony William Tolcher},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 14_suppl},
  pages={3050}
}
3050 Background: EGFR is over-expressed in >80% of renal neoplasms and is implicated in tumor initiation and progression. Antitumor activity against RCC in the phase I study of OSI-774, a selective oral quinazoline inhibitor of EGFR tyrosine kinase (EGFR-TK) activity, has lead to a 2-stage Phase II evaluation in patients (pts) with advanced RCC. METHODS OSI-774 (150mg) was administered daily using 28-day courses, until disease progression. A single dose reduction to 100 mg daily was allowed… CONTINUE READING